Association of Obesity and Type 2 Diabetes with Non-Hodgkin Lymphoma: The Multiethnic Cohort.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
02 Oct 2023
02 Oct 2023
Historique:
received:
17
05
2023
revised:
24
07
2023
accepted:
07
08
2023
pmc-release:
02
04
2024
pubmed:
9
8
2023
medline:
9
8
2023
entrez:
9
8
2023
Statut:
ppublish
Résumé
Given the role of the immune system in non-Hodgkin lymphoma (NHL) etiology, obesity and type 2 diabetes (T2D) may impact NHL development. We examined the association of body mass index (BMI) and T2D with NHL in the multiethnic cohort (MEC). The MEC recruited >215,000 participants in Hawaii and Los Angeles from five racial/ethnic groups; NHL cases were identified through cancer registry linkages. T2D status, and BMI at age 21 and cohort entry were derived from repeated self-reports; for T2D, Medicare claims were also applied. HRs and 95% confidence intervals (CI) for BMI and T2D as predictors of NHL were determined using Cox regression adjusted for relevant covariates. Among 192,424 participants, 3,472 (1.8%) with NHL and 68,850 (36%) with T2D after 19.2 ± 6.6 years follow-up, no significant association between T2D and NHL (HR, 1.04; 95% CI, 0.96-1.13) was observed. Stratification by BMI at cohort entry showed a significant association of T2D with NHL among individuals with normal weight only (HR, 1.18; 95% CI, 1.03-1.37). In a model with both BMI values plus T2D, only overweight (HR, 1.13; 95% CI, 1.01-1.26) and obesity (HR, 1.25; 95% CI, 0.99-1.59) at age 21 were associated with NHL incidence. Stratification by sex, race/ethnicity, and NHL subtype indicated no differences. Our findings suggest an association between T2D and NHL incidence in several subgroups but not in the total population and an elevated risk related to early-life BMI. Excess body weight in early life, rather than T2D, may be a predictor of NHL incidence.
Sections du résumé
BACKGROUND
UNASSIGNED
Given the role of the immune system in non-Hodgkin lymphoma (NHL) etiology, obesity and type 2 diabetes (T2D) may impact NHL development. We examined the association of body mass index (BMI) and T2D with NHL in the multiethnic cohort (MEC).
METHODS
UNASSIGNED
The MEC recruited >215,000 participants in Hawaii and Los Angeles from five racial/ethnic groups; NHL cases were identified through cancer registry linkages. T2D status, and BMI at age 21 and cohort entry were derived from repeated self-reports; for T2D, Medicare claims were also applied. HRs and 95% confidence intervals (CI) for BMI and T2D as predictors of NHL were determined using Cox regression adjusted for relevant covariates.
RESULTS
UNASSIGNED
Among 192,424 participants, 3,472 (1.8%) with NHL and 68,850 (36%) with T2D after 19.2 ± 6.6 years follow-up, no significant association between T2D and NHL (HR, 1.04; 95% CI, 0.96-1.13) was observed. Stratification by BMI at cohort entry showed a significant association of T2D with NHL among individuals with normal weight only (HR, 1.18; 95% CI, 1.03-1.37). In a model with both BMI values plus T2D, only overweight (HR, 1.13; 95% CI, 1.01-1.26) and obesity (HR, 1.25; 95% CI, 0.99-1.59) at age 21 were associated with NHL incidence. Stratification by sex, race/ethnicity, and NHL subtype indicated no differences.
CONCLUSIONS
UNASSIGNED
Our findings suggest an association between T2D and NHL incidence in several subgroups but not in the total population and an elevated risk related to early-life BMI.
IMPACT
UNASSIGNED
Excess body weight in early life, rather than T2D, may be a predictor of NHL incidence.
Identifiants
pubmed: 37555836
pii: 728395
doi: 10.1158/1055-9965.EPI-23-0565
pmc: PMC10592150
mid: NIHMS1925327
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1348-1355Subventions
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA244073
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA229110
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Informations de copyright
©2023 American Association for Cancer Research.
Références
Crit Rev Oncol Hematol. 2018 Sep;129:113-123
pubmed: 30097229
Gastroenterology. 2019 Mar;156(4):966-975.e10
pubmed: 30445012
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1962-70
pubmed: 19531680
Endocrinol Metab Clin North Am. 2014 Mar;43(1):167-85
pubmed: 24582097
Ann Epidemiol. 2011 Jul;21(7):526-35
pubmed: 21497517
BMC Health Serv Res. 2014 Apr 03;14:150
pubmed: 24693862
Blood. 2012 May 24;119(21):4845-50
pubmed: 22496152
J Nutr. 2020 Jul 1;150(7):1880-1888
pubmed: 32338763
Blood. 2007 Jul 15;110(2):695-708
pubmed: 17389762
Am J Epidemiol. 2015 Jun 1;181(11):917-9
pubmed: 25841869
Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):196-203
pubmed: 18187389
Cancer Causes Control. 1996 Mar;7(2):224-30
pubmed: 8740735
Med Sci (Basel). 2021 Jan 30;9(1):
pubmed: 33573146
Prev Chronic Dis. 2019 Feb 21;16:E22
pubmed: 30789820
Blood. 2010 Nov 18;116(20):e90-8
pubmed: 20699439
BMJ. 2015 Jan 02;350:g7607
pubmed: 25555821
J Gen Intern Med. 2022 Jun;37(8):1902-1909
pubmed: 34109541
Diabetes Metab. 2020 Feb;46(1):8-19
pubmed: 31039401
Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):610-612
pubmed: 29511039
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1105-13
pubmed: 27197296
Hematology. 2019 Dec;24(1):527-532
pubmed: 31262228
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):15-25
pubmed: 25174023
Diabetes Metab. 2019 Oct;45(5):458-464
pubmed: 31129317
Diabetes. 2009 Aug;58(8):1732-8
pubmed: 19258435
Sci Rep. 2022 Nov 14;12(1):19475
pubmed: 36376533
Metabolism. 2012 Jul;61(7):1003-9
pubmed: 22237115
Eur J Cancer. 2011 Nov;47(16):2422-30
pubmed: 21733676
Blood. 2008 Dec 15;112(13):5150-60
pubmed: 18796628
Am J Epidemiol. 2000 Feb 15;151(4):346-57
pubmed: 10695593
Int J Cancer. 2009 Sep 15;125(6):1440-5
pubmed: 19444913
Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):253-9
pubmed: 16839219
Eur J Cancer Prev. 2016 Mar;25(2):149-54
pubmed: 25793918
Int J Cancer. 2008 May 1;122(9):2062-70
pubmed: 18167059
Diabetes Care. 2008 Dec;31(12):2391-7
pubmed: 19033419
Obes Rev. 2002 Aug;3(3):141-6
pubmed: 12164465